June 27 | 2019
Sista dag för handel med BTA 1 i 2cureX AB
Read more
June 20 | 2019
2cureX appoints Dr. Med. Henrik Harling as Chief Medical Officer
Read more
June 20 | 2019
2cureX utser Dr. Henrik Harling till Chief Medical Officer
Read more
May 28 | 2019
Kommuniké från årsstämma i 2cureX AB (publ)
Read more
May 28 | 2019
Communique from the Annual General Meeting in 2cureX AB (publ)
Read more
May 28 | 2019
Kraftigt övertecknad företrädesemission i 2cureX AB
Read more
May 28 | 2019
Significantly oversubscribed rights issue in 2cureX AB
Read more
May 9 | 2019
CORRECTION: 2cureX publishes interim report for the first quarter of 2019
Read more
May 9 | 2019
Idag inleds teckningstiden i 2cureX företrädesemission
Read more
May 9 | 2019
Today, the subscription period starts in 2cureX’s rights issue
Read more
May 8 | 2019
2cureX offentliggör memorandum inför företrädesemissionen
Read more
May 8 | 2019
2cureX publishes memorandum ahead of the rights issue
Read more
May 8 | 2019
2cureX publishes interim report for the first quarter of 2019
Read more
May 8 | 2019
2cureX offentliggör delårsrapport för det första kvartalet 2019
Read more
May 7 | 2019
2cureX publishes the annual report for the fiscal year 2018
Read more
May 7 | 2019
2cureX offentliggör årsredovisning för räkenskapsåret 2018
Read more
April 24 | 2019
2cureX beslutar om företrädesemission inför marknadslansering av IndiTreat®
Read more
April 24 | 2019
2cureX decides on rights issue prior to market launch of IndiTreat®
Read more